The Left's Ugly Reaction to Hydroxychloroquine
National Review via Instapundit
A widely shared, four-person-bylined, "wow"-provoking New York Times story today informs us that Donald Trump is personally benefiting from his "aggressive advocacy" of the anti-malaria drug hydroxychloroquine because he owns stock in one of the companies that manufacture the drug.
...In any event, the crack team at the New York Times thinks it’s unfurled the mystery. "As of last year," reports the paper, "Mr. Trump reported that his three family trusts each had investments in a Dodge & Cox mutual fund, whose largest holding was in Sanofi."
As far as we know, Trump probably owns less than $100 of Sanofi stock in one of his mutual funds. If things go well, say he triples his position, Trump will be taking in upwards of $300. Art of the Deal, indeed.
Even if, as I think, this is a typo and he owns $100K, the logic still applies. Trump gives away $400K POTUS salary every year.
Though it’s unlikely. Sanofi is a French drugmaker that produces the hydroxychloroquine-label Plaquenil. The drug, however, isn’t patented, it isn’t particularly difficult to manufacture, and there are a bunch of giant pharma companies around the world already ramping up production of generic versions. Sanofi is less likely to benefit than Novartis or Bayer (check everyone’s mutual funds, pronto!).
... Media keeps asserting that Trump is "ignoring the experts." Well, the president didn’t induce South Korean doctors to use hydroxychloroquine. He didn’t induce Indian doctors to use it. I assume American doctors who are now "off-labeling" the drug to patients have some medical reasons behind their thinking.
Comment at Instapundit: Nor should it escape your attention that the New York Times will assign four reporters to write an amateurish hit job, but not a single one to mention serious rape allegations against the leading Democratic Party presidential candidate by a former staffer.
Posted by: g(r)omgoru 2020-04-09